Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
6.680
+1.910 (+40.04%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
672,760
Open
5.240
Bid (Size)
6.860 (3)
Ask (Size)
6.900 (95)
Prev. Close
4.770
Today's Range
5.190 - 7.223
52wk Range
0.1800 - 7.950
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.
December 20, 2024
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.
Via
News Direct
Exposures
Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 19, 2024
Via
Benzinga
Performance
YTD
+470.94%
+470.94%
1 Month
+3119.28%
+3119.28%
3 Month
+3236.66%
+3236.66%
6 Month
+1608.44%
+1608.44%
1 Year
+456.67%
+456.67%
More News
Read More
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
December 19, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
December 16, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
December 12, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
December 03, 2024
Via
Benzinga
Mainz Biomed Announces Stock Split
November 29, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test
November 22, 2024
Via
News Direct
The Oncology Bet Is Already Paying Off For Pfizer
November 13, 2024
Via
Benzinga
Exposures
COVID-19
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening
November 13, 2024
Via
News Direct
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
November 12, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
What Mainz Biomed (NASDAQ: MYNZ) Has Been Up To Recently And Why Frankie Muniz Is A Backer
November 12, 2024
Via
News Direct
Exposures
Product Safety
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
October 21, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 14, 2024
Via
Benzinga
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
October 10, 2024
Via
Benzinga
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
October 08, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
October 07, 2024
Via
Benzinga
Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early
October 07, 2024
Via
News Direct
The Covid Era Tech Promises To Reinvent Cancer Treatment
October 01, 2024
Via
Benzinga
Exposures
COVID-19
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
October 01, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
September 27, 2024
Via
Benzinga
Pfizer Advances On Its Cancer Journey
September 20, 2024
Via
Benzinga
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
September 18, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.